Scott Gottlieb, MD, is one busy guy. One day he's putting the finishing touches on a policy paper for the American Enterprise Institute, the nonpartisan conservative think tank where he is a resident fellow. The next day he's testifying before Congress about Medicare costs. And the day after that, he's off to New York to fulfill his duty as an internist at NYU's Tisch Hospital. Then it's a red-eye to California for a meeting at Combimatrix, where he's on the board of directors, followed by a flight back to Washington, during which he's cranking out an op-ed piece for the Wall Street Journal.
Such is the life of a man who, at age 39, has achieved more than most people do in a lifetime. Since earning his MD at Mt. Sinai School of Medicine in 1999, Gottlieb has become a leading expert on health policy, regulation, and technology-due in part to his service in various capacities deep within our country's healthcare policymaking apparatus. From 2005 to 2007, he was deputy commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration -the FDA's No. 2 job-prior to that, he served as a senior policy adviser at the Centers for Medicare and Medicaid Services, where he was instrumental in the development of Medicare Part D. He also has had consulting roles with several biotech and pharmaceutical companies. Gottlieb is a charter member of the editorial board of Biotechnology Healthcare.
Yet, for all his influence, Gottlieb presents himself with grace and humility. Five minutes into our conversation, Gottlieb asks, "Am I rambling?"
It took Biotechnology Healthcare about seven weeks to catch up with Gottlieb, and we think it was worth the chase. In a wide-ranging interview with senior contributing writer Michael D. Dalzell, Gottlieb shares his thoughts on healthcare reform and its effects on health policy, biologics, and managed care.
Scott Gottlieb, M.D., is a resident fellow at AEI